Blueprint Medicines Corp (BPMC) Peer Comparison

$129.46

$0.00 (0.00%)

As on 18-Jul-2025 09:30EDT

Market cap

$8,372 Mln

Revenue (TTM)

$562 Mln

P/E Ratio

--

P/B Ratio

24.4

Div. Yield

0 %

Edit

	Blueprint Medicines Corp (BPMC)	OncoCyte Corp (OCX)	Kronos BioÂ Inc (KRON)
Market cap ($ Mln)	8,372	92	54
Revenue ($ Mln)	562	4	9
Net Profit ($ Mln)	-155.73	-58.21	-64.49
Net Margin (%)	-27.70	-1,514.57	-701.53
RoE (%)	-47.53	-584.12	-67.54
Price to Earnings	--	--	--
Price-To-Book	24.44	7.92	0.67

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Blueprint Medicines Corp (BPMC)	OncoCyte Corp (OCX)	Kronos BioÂ Inc (KRON)
Operating Revenue	562.12	3.84	9.19
Cost of Revenue	23.39	1.44	0.83
Gross Profit	488.66	0.74	9.85
Operating Expenses	713.04	60.81	79.53
Operating Profit (EBIT)	-174.31	-58.57	-70.34
Other Income	0.00	0.00	0.00
Profit before Tax	-153.89	-58.21	-64.49
Provision for Tax	1.84	0.00	0.00
Profit after Tax (Net Income)	-155.73	-58.21	-64.49
Minority Interest	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00

Liabilities ($ Mln)

	Blueprint Medicines Corp (BPMC)	OncoCyte Corp (OCX)	Kronos BioÂ Inc (KRON)
Shareholder's Funds	342.13	10.22	79.81
Minority Interest	0.00	0.00	0.00
Non-Current Liabilities	602.89	40.46	20.45
Current Liabilities	250.58	9.68	7.88
Total Liabilities	1,179.81	35.08	124.36

Assets ($ Mln)

	Blueprint Medicines Corp (BPMC)	OncoCyte Corp (OCX)	Kronos BioÂ Inc (KRON)
Non-Current Assets	493.54	24.10	6.27
Current Assets	702.07	36.26	101.87
Total Assets	1,179.81	35.08	124.36
Total Debt*	122.75	3.48	24.09
Net Current Assets	451.49	26.58	93.99

Cashflow ($ Mln)

	Blueprint Medicines Corp (BPMC)	OncoCyte Corp (OCX)	Kronos BioÂ Inc (KRON)
Cash From Operating Activities	-192.59	-20.71	-65.44
Cash Flow from Investing Activities	-47.50	--	85.44
Cash from Financing Activities	273.11	20.43	0.25
Net Cash Inflow / Outflow	--	--	--

Ratios

Profitability Ratios

	Blueprint Medicines Corp (BPMC)	OncoCyte Corp (OCX)	Kronos BioÂ Inc (KRON)
ROCE (%)	-10.09	-611.12	-57.42
ROE (%)	-47.53	-584.12	-67.54
ROA (%)	-11.57	-77.95	-40.55
EBIT Margin (%)	-19.26	-1,349.41	-550.46
Net Margin (%)	-27.70	-1,514.57	-701.53
Cash Profit Margin (%)	0.00	0.00	0.00

Growth Ratios

	Blueprint Medicines Corp (BPMC)	OncoCyte Corp (OCX)	Kronos BioÂ Inc (KRON)
Revenue Growth (%)	99.19	178.08	21.15
EBIT Growth (%)	74.53	-157.26	53.53
Net Profit Growth (%)	45.98	-45.72	44.60
EPS Growth (%)	48.84	--	46.44
Book Value Growth (%)	10.47	--	-42.96

Valuation Ratios

	Blueprint Medicines Corp (BPMC)	OncoCyte Corp (OCX)	Kronos BioÂ Inc (KRON)
Price / Earnings	-82.06	--	-0.67
Price / Book Value	18.43	--	0.65
Dividend Yield (%)	--	--	--
EV/EBITDA	260.78	0.08	0.49
Market Cap ($ Cr)	--	--	--

Solvency Ratios

	Blueprint Medicines Corp (BPMC)	OncoCyte Corp (OCX)	Kronos BioÂ Inc (KRON)
Debt to Equity	1.01	0.00	0.00
Short term debt to equity ratio	0.17	0.14	0.05
Current Ratio	2.80	3.75	12.93
Quick Ratio	2.75	3.70	12.93
Interest Coverage	-1.49	-592.93	-13.30

Operating Efficiency Ratios

	Blueprint Medicines Corp (BPMC)	OncoCyte Corp (OCX)	Kronos BioÂ Inc (KRON)
Debtors to sales (%)	14.20	92.12	0.00
Asset Turnover	0.42	0.05	0.06
Receivable days	43.35	203.60	--
Inventory Days	315.51	65.62	--
Payable days	104.16	517.30	140.96
Cash Conversion Cycle	254.70	-248.08	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly